|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM343106841 |
| 003 |
DE-627 |
| 005 |
20231226015647.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2022 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202202612
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1143.xml
|
| 035 |
|
|
|a (DE-627)NLM343106841
|
| 035 |
|
|
|a (NLM)35790035
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Teal, Carter J
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Directed Evolution Enables Simultaneous Controlled Release of Multiple Therapeutic Proteins from Biopolymer-Based Hydrogels
|
| 264 |
|
1 |
|c 2022
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 26.08.2022
|
| 500 |
|
|
|a Date Revised 26.08.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2022 Wiley-VCH GmbH.
|
| 520 |
|
|
|a With the advent of increasingly complex combination strategies of biologics, independent control over their delivery is the key to their efficacy; however, current approaches are hindered by the limited independent tunability of their release rates. To overcome these limitations, directed evolution is used to engineer highly specific, low affinity affibody binding partners to multiple therapeutic proteins to independently control protein release rates. As a proof-of-concept, specific affibody binding partners for two proteins with broad therapeutic utility: insulin-like growth factor-1 (IGF-1) and pigment epithelium-derived factor (PEDF) are identified. Protein-affibody binding interactions specific to these target proteins with equilibrium dissociation constants (KD ) between 10-7 and 10-8 m are discovered. The affibodies are covalently bound to the backbone of crosslinked hydrogels using click chemistry, enabling sustained, independent, and simultaneous release of bioactive IGF-1 and PEDF over 7 days. The system is tested with C57BL/6J mice in vivo, and the affibody-controlled release of IGF-1 results in sustained activity when compared to bolus IGF-1 delivery. This work demonstrates a new, broadly applicable approach to tune the release of therapeutic proteins simultaneously and independently and thus the way for precise control over the delivery of multicomponent therapies is paved
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a affibodies
|
| 650 |
|
4 |
|a controlled release
|
| 650 |
|
4 |
|a directed evolution
|
| 650 |
|
4 |
|a yeast display
|
| 650 |
|
7 |
|a Biopolymers
|2 NLM
|
| 650 |
|
7 |
|a Delayed-Action Preparations
|2 NLM
|
| 650 |
|
7 |
|a Hydrogels
|2 NLM
|
| 650 |
|
7 |
|a Insulin-Like Growth Factor I
|2 NLM
|
| 650 |
|
7 |
|a 67763-96-6
|2 NLM
|
| 700 |
1 |
|
|a Hettiaratchi, Marian H
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ho, Margaret T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ortin-Martinez, Arturo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ganesh, Ahil N
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Pickering, Andrew J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Golinski, Alex W
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hackel, Benjamin J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wallace, Valerie A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shoichet, Molly S
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 34(2022), 34 vom: 21. Aug., Seite e2202612
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:34
|g year:2022
|g number:34
|g day:21
|g month:08
|g pages:e2202612
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202202612
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 34
|j 2022
|e 34
|b 21
|c 08
|h e2202612
|